Trinseo PLC and twelve affiliated entities filed prepackaged Chapter 11 petitions in the United States Bankruptcy Court for the Southern District of Texas, Houston Division, on May 25 and 26, 2026. The cases are jointly captioned In re: Trinseo PLC, et al., Case No. 26-90545 (CML). The company entered court already holding the support it needed: holders of approximately 78% of its roughly $2.9 billion in total funded debt signed a Restructuring Support Agreement on May 13, 2026, and solicitation began before the petition was filed.

The plan does the work a balance sheet restructuring is supposed to do. It contemplates cutting roughly $2.0 billion of funded debt, backstops a $450 million equity rights offering, funds the cases with $142.5 million of new money, and leaves every general unsecured creditor unimpaired and paid in full. The first day relief is designed to keep the operating business running without interruption, with suppliers, wages, and employee obligations paid in the ordinary course.

One creditor stands apart. CastleKnight Management LP, which holds 2028 OpCo Term Loans and 2L 2029 Notes, did not sign the RSA and has advised that it will object to confirmation. The debtors say they will pursue a consensual resolution but are prepared to litigate. That posture, and the reasons behind it, run through the rest of this report.

The near-term calendar is compressed in the way prepackaged cases tend to be. The proposed voting deadline is June 29, 2026, which also serves as the deadline to object to the disclosure statement and the plan. A combined disclosure-statement-and-confirmation hearing is targeted for July 9, 2026, with a confirmation order milestone of July 25, 2026, sixty days after the petition date. The plan is not expected to go effective for some time after that. The outside date for effectiveness is November 21, 2026, which builds in room for regulatory approvals and an ancillary Irish proceeding addressed later in this report.

Trinseo is a global specialty chemical manufacturer. It makes plastics and latex binders that end up in building materials, automotive components, paper and packaging, appliances, textiles, and consumer electronics. The footprint is large and genuinely global: 32 manufacturing plants and one recycling facility across 28 sites in 14 countries, supported by 11 research and development facilities. The company employs roughly 2,800 people worldwide. Only about 718 of them work for the filing debtors, almost all in the United States. The remainder of the worldwide workforce sits outside the filing entities.

The business runs through three reporting segments. Engineered Materials covers rigid thermoplastic compounds and PMMA sheet and resin products. Latex Binders covers SB latex and styrene-acrylic latex used in paper, carpet, and coatings. Polymer Solutions covers ABS, polystyrene, and recycled materials. A non-debtor affiliate also holds a 50% interest in Americas Styrenics LLC, a styrenics joint venture with Chevron Phillips Chemical Company that sits outside the cases.

The corporate history matters because it explains the cross-border complexity. The business was carved out of The Dow Chemical Company in 2009 under the name Styron, acquired by Bain Capital in 2010, and taken public in 2014 on the New York Stock Exchange under the ticker TSE. The parent, Trinseo PLC, is incorporated in Ireland. On March 30, 2026, the parent was delisted from the NYSE for failing to meet continued listing standards, and its shares now trade on the OTC Pink market. The Irish incorporation and the equity cancellation it requires shape the timeline in ways a purely domestic filing would not.

The distress here is industry-wide before it is company-specific. The disclosure statement describes a chemicals market under sustained pressure from global overcapacity, particularly in Asia-Pacific, persistent pricing pressure, weakened demand, elevated energy costs, rising oil prices beginning in March 2026, geopolitical uncertainty, and tariffs. Demand recovery is not expected until 2027 at the earliest.

The revenue trend tells the first half of the story. Consolidated net sales fell from $3.675 billion in 2023 to $3.513 billion in 2024 to $2.975 billion in 2025, a decline of roughly $700 million over two years.

The second half of the story is the mismatch between earnings and debt. The revenue decline compressed margins to the point that 2025 adjusted EBITDA came in at $162.5 million. That earnings figure, set against roughly $2.9 billion of total indebtedness, is the imbalance the restructuring is designed to address. The NYSE delisting in March 2026 then fed back into the operating business, contributing to credit rating pressure and a contraction in trade terms, which tightened liquidity further just as oil prices were climbing.

To understand who recovers what under this plan, you have to start with where the debt sits. Trinseo’s funded debt is split across two separate collateral silos, identified in the filings as “OpCo” and “Super HoldCo,” each with its own borrowers, guarantors, and collateral packages, and each governed by its own intercreditor arrangements established in January 2025. That silo structure is the reason a revolving lender and a term lender in the same company can sit at opposite ends of the recovery spectrum.

Two features of this stack drive the rest of the case. First, the $1,508 million OpCo Intercompany Term Loan is the single largest piece of the structure, and it is an intercompany obligation rather than third-party debt, which is why it becomes the subject of an independent investigation and settlement discussed below. Second, the priority of the same lender group changes depending on which collateral pool is being tested, a complexity the disclosure statement maps across multiple collateral priority charts. The takeaway for a newsletter reader is simpler than the charts: position in the silo, not seniority in the abstract, determines recovery here.

The RSA assembles four moving parts: new financing for the cases, an equity raise, a large debt reduction, and exit financing to carry the reorganized company forward. The support behind it is concentrated at the top of the structure. As measured against the relevant claim pools, the agreement is backed by approximately 100% of RCF claims, approximately 99.9% of Super HoldCo 1L claims, and approximately 86% of OpCo term loan claims.

DIP financing

The cases are funded by two debtor-in-possession facilities totaling $427.5 million. The new money portion is $142.5 million; the remainder is a roll-up of prepetition claims at a 2:1 ratio. The Super HoldCo DIP facility is $157.5 million ($52.5 million new money plus $105 million of rolled-up Super HoldCo 1L claims). The OpCo DIP facility is $270 million ($90 million new money plus $180 million of rolled-up RCF claims). New money under both facilities prices at SOFR plus 9.00%, subject to a 3% floor.

From the old stack to the new one

The combined effect of the deleveraging, the equity raise, and the exit financing is to replace roughly $2.9 billion of prepetition funded debt with a far lighter post-emergence structure. The reorganized company is contemplated to be a privately held Delaware entity, not subject to SEC reporting and not listed on any exchange, with the debtors using commercially reasonable efforts to stay below 300 record holders.

The equity rights offering is the mechanism that converts creditor support into post-emergence ownership. The $450 million offering is allocated mainly to eligible holders of Super HoldCo 1L claims and OpCo term loan claims, with commitment parties receiving premium interests for backstopping the raise. Proceeds follow a defined waterfall that repays the OpCo DIP and the Super HoldCo new money DIP before reaching other distributions.

Every prepackaged case with overwhelming support still has to account for the creditors who did not sign. Here, that creditor is CastleKnight Management LP. It holds 2028 OpCo Term Loans and 2L 2029 Notes, and it was once a member of the 2028 OpCo Ad Hoc Group before stepping away. It has not executed the RSA and has stated that it will object to confirmation.

The reason the dispute matters becomes clear when you look at where CastleKnight’s claims sit. The OpCo term loan class is projected to recover 2% to 9% under the plan. That is the thinnest recovery of any class entitled to vote, and it reflects the silo structure: after the intercompany settlement and the priority arrangements, the OpCo collateral package leaves little value flowing to that tranche. The plan’s allocations, releases, and intercompany settlement bear directly on what this class receives.

The plan treats CastleKnight accordingly. It is carved out of the defined Released Parties under the third-party release provisions, alongside the Minority Ad Hoc Group members and any party that breaches the intercreditor agreements. The third-party release itself runs on an opt-out basis for voting and presumed-accepting classes and an opt-in basis for classes deemed to reject. None of this is resolved. The objection deadline has not passed, and confirmation is contested rather than assured.

The plan sorts claims into twelve classes. Three are entitled to vote, and their projected recoveries map the silo structure almost perfectly: the higher in the priority waterfall, the larger the recovery. General unsecured creditors, notably, ride above the dispute entirely. They are unimpaired and paid in full in the ordinary course, which keeps trade partners and ordinary vendors whole and the operating business stable.

The case for confirming over an objection rests on the best interests test. The plan compares its projected recoveries to what each class would receive in a hypothetical Chapter 7 liquidation, and for every impaired class the plan does at least as well, usually far better. A liquidation of a chemicals business spread across 14 countries would destroy the going-concern value the plan preserves.

The comparison is most pointed in the OpCo term loan class. Its projected plan recovery of 2% to 9% is low, but the liquidation alternative the analysis assigns to that class is zero. That is the response the disclosure statement frames to a best interests challenge, and it is the same class from which the objection originates.

Centerview Partners prepared the valuation that underpins the recovery estimates, working as of May 19, 2026, and drawing on a discounted cash flow analysis, a comparable company analysis, and a precedent transactions analysis. The result places enterprise value in a range of $1,450 million to $1,950 million, with a midpoint of $1,700 million, and total equity value at $580 million to $1,080 million, midpoint $830 million. With roughly $2.9 billion of funded debt sitting above that equity value, there is not enough value to reach far down the capital structure, which is what the class-by-class recovery estimates reflect.

The forward case rests on a recovery that the projections push out across the rest of the decade. Projected adjusted EBITDA climbs from $89 million in the second half of 2026 to $343 million by 2030, with projected net sales returning to the $3.5 billion to $3.9 billion range. These are projections, not results, and they assume the demand recovery the company expects beginning in 2027.

The projections also support the feasibility case under the Bankruptcy Code. A reorganized company carrying $850 million of exit term debt against EBITDA building toward $343 million is a far more serviceable structure than the one it replaces. The projected cash balance stays positive throughout, ranging from $170 million to $589 million across the projection period.

The wrinkle that separates this case from an otherwise routine domestic prepackaged plan is the parent company’s Irish incorporation. Cancelling the existing equity in an Irish PLC cannot be accomplished by a United States confirmation order alone. The plan therefore contemplates an ancillary Irish proceeding, an examinership and scheme of arrangement, to give effect to the equity cancellation under Irish law.

That proceeding carries its own timetable. Irish examinership provides a protection period of up to 100 calendar days, extendable up to a year, and an Irish confirmation order is a condition precedent to the plan going effective in the United States. The scheme of arrangement must clear one of several approval thresholds, including approval by a majority of impaired creditors or by a majority of voting classes. This is why the outside date for effectiveness sits at November 21, 2026, well after the targeted July confirmation, with a further 90-day extension available for regulatory approvals. Confirmation and effectiveness are not the same finish line here. The disclosure statement attributes the gap between them to both the necessary regulatory approvals and the ancillary Irish proceeding.

The path from petition to emergence is mapped by a series of milestones in the RSA and the proposed scheduling. The prepetition steps assembled the deal; the postpetition steps execute it on a compressed schedule, subject to the Irish proceeding running in parallel.

These dates are targets, not certainties. The combined hearing date is subject to the court’s calendar, the objection deadline has not run, and the effective date depends on the Irish proceeding and any required regulatory clearances. A contested confirmation could move the schedule.

Read across the structure, the plan produces a clear hierarchy of outcomes. The top of the stack is made nearly whole, the middle recovers a majority of its claims, the bottom of the OpCo silo recovers almost nothing, and existing equity is cancelled. Trade creditors and the operating business are unaffected.

What happens next turns on two open questions. The first is whether the debtors reach a consensual resolution with the holdout or confirm over its objection, which will test the plan’s release framework, intercompany settlement, and best interests showing. The second is whether the Irish proceeding stays on its parallel track so that confirmation in July can convert into an effective plan before the November outside date. Neither is resolved as of the filings analyzed here.